Bisindolylmaleimide VIII

Bisindolylmaleimide VIII (Ro 31-7549) is a potent and selective protein kinase C (PKC) inhibitor with an IC50 of 158 nM for rat brain PKC. Bisindolylmaleimide VIII has IC50s of 53, 195, 163, 213, and 175 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, PKC-ε, respectively[1]. Bisindolylmaleimide VIII facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases[1][2].

Product Specifications

CAS Number

[125313-65-7]

Product Name Alternative

Ro 31-7549; Bis VIII

UNSPSC

12352005

Target

Apoptosis; PKC

Type

Reference compound

Related Pathways

Apoptosis; Epigenetics; TGF-beta/Smad

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/bisindolylmaleimide-viii.html

Solubility

10 mM in DMSO

Smiles

O=C(C(C1=CN(CCCN)C2=C1C=CC=C2)=C3C4=CN(C)C5=C4C=CC=C5)NC3=O

Molecular Formula

C24H22N4O2

Molecular Weight

398.46

References & Citations

[1]Wilkinson SE, et al. Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C. Biochem J. 1993 Sep 1;294 (Pt 2) :335-7.|[2]Ohtsuka T, et al. Bisindolylmaleimide VIII enhances DR5-mediated apoptosis through the MKK4/JNK/p38 kinase and the mitochondrial pathways. J Biol Chem. 2002 Aug 9;277 (32) :29294-303.